

INVITATION



Meet our CEO Jennifer Chow

Location	Date	Time	Venue
Sydney	Monday, 7 March 2022	4:30pm-6:30pm	Radisson Blu Plaza Hotel 27 O'Connell Street
Melbourne	Tuesday, 8 March 2022	4:30pm-6:30pm	Garden State Hotel, Observatory room 101 Flinders Lane

R S V P Please register your interest to attend a shareholder and management reception by **3 March 2022**.

Email: alison@chimerictherapeutics.com



Marking our Birthday!

Although we usually issue our shareholder newsletter at the end of each quarter, I wanted to take a moment to highlight our one-year anniversary and invite you to come and meet with me in Australia in early March!



JENNIFER CHOW
Chief Executive Officer
and Managing Director

18 January 2022, marked the one-year anniversary of our IPO on the ASX and what an incredible year it has been! I sincerely want to thank everyone for the support that you have shown us over the past year as we have rapidly grown to be the leader in cell therapy development and a fast-growing cell therapy company in Australia.

Those of you that were with us at this time last year will remember that we were developing one asset (our CLTX CAR T), in one disease area (brain cancer), and with one clinical trial when we launched onto the ASX in January 2021.

Today, just a short 12 months later, I am proud to say that we now have seven assets in development, with eight clinical trial programs planned to address patient needs, in more than ten different types of cancer.

Our lead asset CHM 1101 (our CLTX CAR T), has also given us reason for optimism this past year with an encouraging initial data set. Although it's early days, the patients that were treated in our initial two dose levels demonstrated safety, with no dose limiting toxicities and remarkably, an early efficacy signal with over 70% of patients achieving local stability of their disease.

This is truly exciting for us, not just because of what it could mean for Chimeric as a company, but for what it could mean for patients who have brain cancer, one of the most fatal types of cancer today.

We're also very pleased with the progress that CHM 2101, our CDH17 CAR T cell therapy from the University of Pennsylvania is making its way towards entering clinical trials.

We recently signed a 3-year sponsored research agreement with the University of Pennsylvania that enables us to work in close collaboration with this world-renowned team. Our aligned objective with the University of Pennsylvania is to rapidly complete all the work necessary to apply to the US FDA for an approval, that will allow us to begin human clinical trials in multiple different types of gastrointestinal cancer.

At the end of last year, we also announced that we had acquired an exclusive option to CHM 0201, the CORE-NK platform. This felt like an early Christmas present to me as NK cell platforms are the most in demand cell therapy platforms today and ours has already been clinically validated. NK cell platforms are transformational for companies like Chimeric as they are "repeatable technologies" – meaning that from the one platform we can develop an unlimited number of assets. We are starting with the development of five Chimeric assets from the platform and will also be exploring additional opportunities for collaborations or partnerships in 2022.

Look for more news on our development plans soon!

One of the other things that you will always hear me talk about is our incredible team. Cell therapy development is highly complex and requires significant experience and expertise to navigate the development path to commercialisation. Chimeric truly benefits from having a team with over 40 years' experience working on more than 25 different cell therapy programs, and most importantly – a team that has been part of the commercialisation of 4/5 of the FDA approved cell therapies. It's this knowledge that has made us the preferred partner for the University of Pennsylvania with our CDH17 CAR T and will enable us to navigate the development of our assets in the most optimal path forward.

Although I could continue for pages about all of the other milestones we have achieved in our first year, I want to take time to acknowledge that even

with all of our exciting growth we have unfortunately not been immune to the challenges of the biotech capital markets over the past few months. In Australia and globally, biotech companies have seen a significant reduction in value often with no rational cause – Chimeric included. Although this has been incredibly disappointing to us – especially with the incredible growth and progress we have seen, we are confident that the market will correct, as we strongly believe in the future value of Chimeric. We truly appreciate all of your ongoing support and your deep commitment to us as we navigate through this.

Finally, I am thrilled to invite you to come and talk with me about all of our development, progress, and plans in person in Australia! With the announcement that Australia will be opening its borders later this month I took the opportunity to book one of the first flights available. I look forward to arriving in Australia in early March and hope to meet as many of you in person as I can during the week of 7-11 March.

I thank you for your continued trust and confidence and look forward to meeting you all soon!

Jenn

